TY - JOUR
T1 - Reduced mRNA expression of the DNA demethylase, MBD2, in human colorectal and stomach cancers
AU - Kanai, Yae
AU - Ushijima, Saori
AU - Nakanishi, Yukihiro
AU - Hirohashi, Setsuo
N1 - Funding Information:
This study was supported by a Grant-in-Aid for the Second Term Comprehensive 10-Year Strategy for Cancer Control and a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare of Japan.
PY - 1999/11/2
Y1 - 1999/11/2
N2 - A study was performed to evaluate the significance of aberrations of the newly identified DNA demethylase, MBD2, in human carcinogenesis. Levels of expression of DNA demethylase mRNA were examined by reverse transcription followed by real-time quantitative detection of the PCR products in 32 samples of colorectal cancer tissue, 24 stomach cancers, and the corresponding noncancerous mucosae. DNA demethylase mRNA levels normalized with glyceraldehyde-phosphate dehydrogenase (GAPDH) mRNA were reduced in 31 (97%) of the 32 colorectal cancers and in 22 (92%) of the 24 stomach cancers when compared with the levels in the corresponding noncancerous mucosae. The average levels of DNA demethylase mRNA expression normalized with GAPDH mRNA in each of the colorectal (0.81 ± 0.55) and stomach (2.88 ± 0.23) cancers were significantly lower than in the noncancerous mucosae (1.90 ± 0.16 and 5.11 ± 0.34, respectively, p < 0.0001). There was no significant association between the DNA demethylase mRNA level and malignant potential in both colorectal and stomach cancers. These data suggest that reduced expression of DNA demethylase may play a role at a certain step of multistage carcinogenesis. Reduction of DNA demethylase mRNA expression may be, if anything, one of the early events of carcinogenesis, but may not participate in the malignant progression of tumors.
AB - A study was performed to evaluate the significance of aberrations of the newly identified DNA demethylase, MBD2, in human carcinogenesis. Levels of expression of DNA demethylase mRNA were examined by reverse transcription followed by real-time quantitative detection of the PCR products in 32 samples of colorectal cancer tissue, 24 stomach cancers, and the corresponding noncancerous mucosae. DNA demethylase mRNA levels normalized with glyceraldehyde-phosphate dehydrogenase (GAPDH) mRNA were reduced in 31 (97%) of the 32 colorectal cancers and in 22 (92%) of the 24 stomach cancers when compared with the levels in the corresponding noncancerous mucosae. The average levels of DNA demethylase mRNA expression normalized with GAPDH mRNA in each of the colorectal (0.81 ± 0.55) and stomach (2.88 ± 0.23) cancers were significantly lower than in the noncancerous mucosae (1.90 ± 0.16 and 5.11 ± 0.34, respectively, p < 0.0001). There was no significant association between the DNA demethylase mRNA level and malignant potential in both colorectal and stomach cancers. These data suggest that reduced expression of DNA demethylase may play a role at a certain step of multistage carcinogenesis. Reduction of DNA demethylase mRNA expression may be, if anything, one of the early events of carcinogenesis, but may not participate in the malignant progression of tumors.
KW - Carcinogenesis
KW - DNA demethylase
KW - DNA methylation
KW - MBD2
UR - http://www.scopus.com/inward/record.url?scp=0033517836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033517836&partnerID=8YFLogxK
U2 - 10.1006/bbrc.1999.1613
DO - 10.1006/bbrc.1999.1613
M3 - Article
C2 - 10544038
AN - SCOPUS:0033517836
SN - 0006-291X
VL - 264
SP - 962
EP - 966
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 3
ER -
